In Battle Over Johnson ’ s Baby Powder, Asbestos Opens a New Legal Front

Johnson&Johnson says its product is safe. But asbestos, a carcinogen that can exist underground near talc, was a concern inside the company for decades.
Source: NYT Health - Category: Consumer Health News Authors: Tags: Asbestos Hazardous and Toxic Substances Product Tests Ovarian Cancer Suits and Litigation (Civil) Mesothelioma Cosmetics and Toiletries Research Johnson & Food and Drug Administration Source Type: news

Related Links:

A woman who claims asbestos in Johnson &Johnson products caused her deadly cancer was awarded $29.4 million by a California jury on Wednesday, Reuters reports. A jury in a California Superior Court in Oakland determined that defective Baby Powder was a “substantial contributing factor” to Terry Leavitt’s mesothelioma, an aggressive cancer that affects the tissue that coats internal organs, the Associated Press reports. Leavitt said she often used two talcum-powder-based Johnson &Johnson products — Baby Powder and Shower to Shower powder — in the 1960s and 1970s, and claims they contrib...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized Cancer onetime Source Type: news
chel L O’Donnell Dysfunctional homologous recombination DNA repair (HRR), frequently due to BRCA mutations, is a determinant of sensitivity to platinum chemotherapy and poly(ADP-ribose) polymerase inhibitors (PARPi). In cultures of ovarian cancer cells, we have previously shown that HRR function, based upon RAD51 foci quantification, correlated with growth inhibition ex vivo induced by rucaparib (a PARPi) and 12-month survival following platinum chemotherapy. The aim of this study was to determine the feasibility of measuring HRR dysfunction (HRD) in other tumours, in order to estimate the frequency and hence wid...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
Johnson &Johnson executives this week revealed the Department of Justice and the Securities and Exchange Commission issued subpoenas related to ongoing lawsuits over the company’s alleged asbestos contamination in its popular talcum powder. The company disclosed the federal inquiries in its annual report to the SEC on Wednesday. It was the first time the pharmaceutical giant admitted that federal agencies had subpoenaed the company about its talc products. Despite thousands of lawsuits and a 2017 report that showed J&J executives were aware of the asbestos liabilities since the 1970s, company officials deny all a...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Seeking protection from rapidly mounting litigation, Imerys Talc America and two of its subsidiaries filed for Chapter 11 bankruptcy protection Wednesday in Delaware. Imerys is a major talc supplier for Johnson &Johnson consumer goods, including the company’s iconic baby powder and Shower to Shower line. Litigants claim the talc-based products were contaminated with asbestos, leading to cases of mesothelioma and ovarian cancer. The bankruptcy filing comes in the midst of an ongoing, high-profile trial in California in which a woman is blaming Imerys talc for her mesothelioma, a rare cancer caused almost exclusi...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Sen. Patty Murray, D-Wash., has questions, and she wants answers from Johnson &Johnson about its iconic baby powder and the reported link to asbestos-related cancers. Murray recently sent a letter to Johnson &Johnson CEO Alex Gorsky, asking for documentation about past testing for asbestos-tainted talc and communication with the FDA regarding the safety of its product. Murray is a ranking member of the Senate Committee on Health, Education, Labor and Pensions. The letter stemmed from an earlier report by Reuters that Johnson &Johnson hid evidence of asbestos in its product for many years and intentionally misle...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Doctors in China may have uncovered an effective second- or third-line treatment option for patients with malignant pleural mesothelioma. Dr. RongQin Meng, an oncologist at 363 Hospital in Cheng Du, said the investigational drug Apatinib (rivoceranib) could become part of a much-needed advance in mesothelioma treatment. After first- and second-line chemotherapy combinations had failed to slow tumor growth in a 58-year-old woman, Apatinib provided a five-month progression-free survival. “I was surprised at the result,” Meng told The Mesothelioma Center at Asbestos.com. “After taking the drug, the quality o...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
This study aimed to explore whether a correlation exists between the incidence and mortality of cancers and normalized internet search volumes on the big data platform, Baidu. We also assessed whether the distribution of people who searched for specific types of cancer differed by gender. Finally, we determined whether there were regional disparities among people who searched the Web for cancer-related information. Methods: Standard Boolean operators were used to choose search terms for each type of cancer. Spearman’s correlation analysis was used to explore correlations among monthly search index values for each can...
Source: Journal of Medical Internet Research - Category: General Medicine Authors: Source Type: research
ConclusionSurvivals beyond 20 months can be obtained with the use of CRS/HIPEC for rare PC etiologies aligning with results of other groups. CRS/HIPEC in well-selected patients demonstrates a clinical benefit and this could be confirmed with a multi-institutional study.
Source: The American Journal of Surgery - Category: Surgery Source Type: research
Shares in Boston Scientific (NYSE:BSX) rose slightly this morning after the company reported preliminary results for the fourth quarter and full year of 2018 that were in-line with estimates on Wall Street. The Marlborough, Mass.-based company said it expects to report $2.56 billion in sales for the fourth quarter and $9.82 billion for the full year. In Q4, Boston Scientific’s cardiovascular business pulled in $970 million in sales, while its rhythm &neuro unit recorded $790 million in revenue. The company’s MedSurg division saw $800 million in sales, according to an SEC filing. Most of the company&rsq...
Source: Mass Device - Category: Medical Devices Authors: Tags: Business/Financial News Featured MassDevice Earnings Roundup Wall Street Beat Alphatec Boston Scientific Hologic ICON plc Integra LifeSciences NovoCure Orthofix SeaSpine Source Type: news
ConclusionThis study demonstrates that patients undergoing AWR have a higher incidence of postoperative WD. CST was associated with an increased incidence of Grade III WC and WD. Patients with a higher PSS were more likely to develop midline wound recurrence.
Source: European Journal of Surgical Oncology (EJSO) - Category: Surgery Source Type: research
More News: Asbestosis | Babies | Cancer | Cancer & Oncology | Food and Drug Administration (FDA) | Health | Legislation | Mesothelioma | Ovarian Cancer | Ovaries | Toxicology